Fresenius SE & Co. (OTCMKTS:FSNUY) Reaches New 52-Week Low – Here’s Why

Posted by Tammy Falkenburg on May 13th, 2026

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) hit a new 52-week low during trading on Wednesday . The stock traded as low as $11.2271 and last traded at $11.27, with a volume of 48031 shares changing hands. The stock had previously closed at $11.71.

Analyst Ratings Changes

Several equities research analysts recently commented on FSNUY shares. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research note on Monday, April 20th. Citigroup restated a “buy” rating on shares of Fresenius SE & Co. in a report on Tuesday, February 3rd. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Fresenius SE & Co. has an average rating of “Buy”.

Check Out Our Latest Report on Fresenius SE & Co.

Fresenius SE & Co. Price Performance

The stock’s 50-day moving average is $12.87 and its 200-day moving average is $14.09. The firm has a market cap of $25.57 billion, a P/E ratio of 15.13 and a beta of 0.68. The company has a quick ratio of 1.00, a current ratio of 1.32 and a debt-to-equity ratio of 0.47.

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The firm had revenue of $6.75 billion during the quarter, compared to analyst estimates of $6.79 billion. Fresenius SE & Co. had a net margin of 6.55% and a return on equity of 10.29%. As a group, equities analysts anticipate that Fresenius SE & Co. will post 1.05 EPS for the current fiscal year.

About Fresenius SE & Co.

(Get Free Report)

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.